These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 10696104

  • 21. Importance of factor Xa in determining the procoagulant activity of whole-blood clots.
    Eisenberg PR, Siegel JE, Abendschein DR, Miletich JP.
    J Clin Invest; 1993 May; 91(5):1877-83. PubMed ID: 8486759
    [Abstract] [Full Text] [Related]

  • 22. Displacement of fibrin-bound thrombin by r-hirudin precludes the use of 131I-r-hirudin for detecting pulmonary emboli in the rabbit.
    Rubens FD, Ross-Ouellet B, Dennie C, Coates G, Kinlough-Rathbone RL, Hatton MW.
    Thromb Haemost; 1994 Aug; 72(2):232-8. PubMed ID: 7831658
    [Abstract] [Full Text] [Related]

  • 23. Inhibition of in vitro clot growth by r-hirudin is more effective and longer sustained than by an analogous peptide.
    Römisch J, Stöhr HA, Stauss H, Koschinsky R, Stüber W, Pâques EP.
    Thromb Haemost; 1994 Mar; 71(3):320-4. PubMed ID: 8029796
    [Abstract] [Full Text] [Related]

  • 24. Determination of prothombinase activation after adding human purified prothrombin to human clot: comparison of hirudin, an activated factor II inhibitor, with DX9065a, an activated factor X inhibitor, on clot-associated thrombin and on prothrombin activation.
    Meddahi S, Bara L, Fessi H, Samama MM.
    Blood Coagul Fibrinolysis; 2005 Mar; 16(2):125-33. PubMed ID: 15741800
    [Abstract] [Full Text] [Related]

  • 25. Effect of non-heparin thrombin antagonists on thrombin generation, platelet function, and clot structure in whole blood.
    Carr ME, Angchaisuksiri P, Carr SL, Martin EJ.
    Cell Biochem Biophys; 2003 Mar; 39(2):89-99. PubMed ID: 14515016
    [Abstract] [Full Text] [Related]

  • 26. High thrombin concentrations in fibrin sealants induce apoptosis in human keratinocytes.
    Gugerell A, Schossleitner K, Wolbank S, Nürnberger S, Redl H, Gulle H, Goppelt A, Bittner M, Pasteiner W.
    J Biomed Mater Res A; 2012 May; 100(5):1239-47. PubMed ID: 22359340
    [Abstract] [Full Text] [Related]

  • 27. The ability of thrombin inhibitors to reduce the thrombin activity generated in plasma on extrinsic and intrinsic activation.
    Prasa D, Svendsen L, Stürzebecher J.
    Thromb Haemost; 1997 Mar; 77(3):498-503. PubMed ID: 9066001
    [Abstract] [Full Text] [Related]

  • 28. The effect of fibrin clots and clot-bound thrombin on the development of platelet procoagulant activity.
    Kumar R, Béguin S, Hemker HC.
    Thromb Haemost; 1995 Sep; 74(3):962-8. PubMed ID: 8571330
    [Abstract] [Full Text] [Related]

  • 29. Higher concentrations of heparin and hirudin are required to inhibit thrombin generation in tissue factor-activated cord plasma than in adult plasma.
    Baier K, Cvirn G, Fritsch P, Köstenberger M, Gallistl S, Leschnik B, Muntean W.
    Pediatr Res; 2005 May; 57(5 Pt 1):685-9. PubMed ID: 15718352
    [Abstract] [Full Text] [Related]

  • 30. A screening procedure to evaluate the anticoagulant activity and the kinetic behaviour of direct thrombin inhibitors.
    Rupin A, Mennecier P, de Nanteuil G, Laubie M, Verbeuren TJ.
    Thromb Res; 1995 May 01; 78(3):217-25. PubMed ID: 7631302
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Construction and in vitro testing of a novel fab-hirudin-based fusion protein that targets fibrin and inhibits thrombin in a factor xa-dependent manner.
    Peter K, Gupta A, Nordt T, Bauer S, Runge MS, Bode C.
    J Cardiovasc Pharmacol; 2003 Aug 01; 42(2):237-44. PubMed ID: 12883328
    [Abstract] [Full Text] [Related]

  • 33. Antithrombin effects of native and recombinant hirudins.
    Markwardt F, Stürzebecher J, Glusa E.
    Biomed Biochim Acta; 1990 Aug 01; 49(5):399-404. PubMed ID: 2271010
    [Abstract] [Full Text] [Related]

  • 34. Probing the Dynamics of Clot-Bound Thrombin at Venous Shear Rates.
    Haynes LM, Orfeo T, Mann KG, Everse SJ, Brummel-Ziedins KE.
    Biophys J; 2017 Apr 25; 112(8):1634-1644. PubMed ID: 28445754
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Decreased thrombin activity of fibrin clots prepared in cord plasma compared with adult plasma.
    Patel P, Weitz J, Brooker LA, Paes B, Mitchell L, Andrew M.
    Pediatr Res; 1996 May 25; 39(5):826-30. PubMed ID: 8726236
    [Abstract] [Full Text] [Related]

  • 37. Whole blood clots are more resistant to lysis than plasma clots--greater efficacy of rivaroxaban.
    Varin R, Mirshahi S, Mirshahi P, Klein C, Jamshedov J, Chidiac J, Perzborn E, Mirshahi M, Soria C, Soria J.
    Thromb Res; 2013 Mar 25; 131(3):e100-9. PubMed ID: 23313382
    [Abstract] [Full Text] [Related]

  • 38. The behavior of human mesenchymal stem cells in 3D fibrin clots: dependence on fibrinogen concentration and clot structure.
    Ho W, Tawil B, Dunn JC, Wu BM.
    Tissue Eng; 2006 Jun 25; 12(6):1587-95. PubMed ID: 16846354
    [Abstract] [Full Text] [Related]

  • 39. Vasoflux, a new anticoagulant with a novel mechanism of action.
    Weitz JI, Young E, Johnston M, Stafford AR, Fredenburgh JC, Hirsh J.
    Circulation; 1999 Feb 09; 99(5):682-9. PubMed ID: 9950667
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.